

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

CLINICAL BENEFIT	☐ MINIMIZE SAFETY RISK OR CONCERN. ☐ MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. ☐ ASSURE APPROPRIATE LEVEL OF CARE. ☐ ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. ☒ ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. ☐ ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	RETIRED 7/1/2026

POLICY

Genetic testing for hereditary pancreatitis may be considered **medically necessary** for individuals aged 18 years and younger with unexplained acute recurrent (>1 episode) or chronic pancreatitis with documented elevated amylase or lipase levels.

Genetic testing for hereditary pancreatitis is considered **investigational** in all other situations. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

POLICY GUIDELINES

Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It was implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Diseased-Assoc.Variant	Disease-associated change in the DNA sequence.
	Variant	Change in DNA sequence
	Familial Variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives.

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely Pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association of Molecular Pathology.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

PRODUCT VARIATIONS

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO: Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

DESCRIPTION/BACKGROUND

In chronic pancreatitis (CP), recurrent attacks of acute pancreatitis evolve into a chronic inflammatory state with exocrine insufficiency, endocrine insufficiency manifested as diabetes, and increased risk for pancreatic cancer. Hereditary pancreatitis (HP) is a subset of CP defined clinically as a familial pattern of CP. Variants of several genes are associated with HP. Demonstration of a pathogenic variant in one or several of these genes can potentially be used to confirm the diagnosis of HP, provide information on prognosis and management, and/or determine the risk of CP in asymptomatic relatives of patients with HP.

Pancreatitis

Acute pancreatitis (AP) and chronic pancreatitis (CP) are caused by trypsin activation within the pancreas, resulting in autodigestion, inflammation, elevation of pancreatic enzymes in serum,

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

and abdominal pain. CP is defined as a state of ongoing inflammation associated with chronic or recurrent symptoms and progression to exocrine and endocrine pancreatic insufficiency.

Alcohol is the major etiologic factor in 80% of CP, which has a peak incidence in the fourth and fifth decades of life. Gall stones, hypercalcemia, inflammatory bowel disease, autoimmune pancreatitis, and peptic ulcer disease can also cause CP. About 20% of CP is idiopathic.

A small percentage of CP is categorized as hereditary pancreatitis (HP), which usually begins with recurrent episodes of AP in childhood and evolves into CP by age 20 years old. Multiple family members may be affected over several generations, and pedigree analysis often reveals an autosomal dominant pattern of inheritance. Clinical presentation and family history alone are sometimes insufficient to distinguish between idiopathic CP and HP, especially early in the course of the disease. Chronic pancreatitis is also associated with comorbidities with known racial health disparities (e.g., diabetes, renal disease, obesity).

HP is associated with a markedly increased risk of pancreatic cancer, although HP patients account for a small fraction of all cases of pancreatic cancer and are only a subset of the 10% of pancreatic cancers that are considered to have a genetic or familial predisposition. Individuals with HP have an estimated 40% to 55% lifetime risk of developing pancreatic cancer.

Genetic Determinants

PRSS1 Variants

Whitcomb (2001) discovered that disease-associated variants of protease, serine, 1 (trypsin 1) (*PRSS1*) on chromosome 7q35 cause HP. *PRSS1* encodes cationic trypsinogen. The gain of function variants of the *PRSS1* gene cause HP by prematurely and excessively converting trypsinogen to trypsin, which results in pancreatic autodigestion. Between 60% and 80% of people who have a disease-associated *PRSS1* variant will experience pancreatitis in their lifetimes; 30% to 40% will develop CP. Most, but not all, people with a disease-associated variant of *PRSS1* will have inherited it from one of their parents. The proportion of HP caused by a de novo variant of *PRSS1* is unknown. In families with 2 or more affected individuals in 2 or more generations, genetic testing has shown that most have a demonstrable disease-associated *PRSS1* variant. In 60% to 100%, the variant is detected by sequencing technology (Sanger or next generation), and duplications of exons or the whole *PRSS1* gene are seen in about 6%. Two *PRSS1* point variants (p.Arg122His, p.Asn291Ile) are most common, accounting for 90% of disease-associated variants in affected individuals. Over 40 other *PRSS1* sequence variants have been found, but their clinical significance is uncertain. Pathogenic *PRSS1* variants are present in 10% or less of individuals with CP.

Targeted analysis of exons 2 and 3, where the common disease-associated variants are found, or *PRSS1* sequencing, are first-line tests, followed by duplication analysis. The general indications for *PRSS1* testing and emphasis on pre- and post-test genetic counseling have remained central features of reviews and guidelines. However, several other genes have emerged as significant contributors to both HP and CP. They include the cystic fibrosis (CF) transmembrane conductance regulator (*CFTR*) gene, a serine protease inhibitor, Kazal type 1 (*SPINK1*) gene, chymotrypsin C (*CTRC*) gene, and claudin-2 (*CLDN2*) gene.

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

CFTR Variants

Autosomal recessive variants of *CFTR* cause CF, a chronic disease with onset in childhood that causes severe sinopulmonary disease and numerous gastrointestinal abnormalities. The signs and symptoms of CF can vary widely. On rare occasions, an affected individual may have mild pulmonary disease, pancreatic exocrine sufficiency, and may present with acute, recurrent acute, or CP. Individuals with heterozygous variants of the *CFTR* gene (CF carriers) have a 3- to 4-fold increased risk for CP. Individuals with 2 *CFTR* pathogenic variants (homozygotes or compound heterozygotes) will benefit from CF-specific evaluations, therapies, and genetic counseling.

SPINK Variants

The *SPINK* gene encodes a protein that binds to trypsin and thereby inhibits its activity. Variants in *SPINK* are not associated with acute pancreatitis but are found, primarily as modifiers, in acute recurrent pancreatitis and seem to promote the development of CP, including for individuals with compound heterozygous variants of the *CFTR* gene. Autosomal recessive familial pancreatitis may be caused by homozygous or compound heterozygous *SPINK* variants.

CTRC Variants

The *CTRC* gene is important for the degradation of trypsin and trypsinogen, and 2 variants (p.R254W, p.K247_R254del) are associated with increased risk for idiopathic CP (odds ratio [OR]=4.6), alcoholic pancreatitis (OR=4.2), and tropical pancreatitis (OR=13.6). Tropical pancreatitis is a disease almost exclusively occurring in the setting of tropical climate and malnutrition.

CLDN2 Variants

The *CLDN2* gene encodes a member of the claudin protein family, which acts as an integral membrane protein at tight junctions and has tissue-specific expression. Several single nucleotide variants in *CLDN2* have been associated with CP.

REGULATORY STATUS

Testing for variants associated with HP is typically done by direct sequence analysis or next-generation sequencing (NGS). A number of laboratories offer testing for the relevant genes, either individually or as panels.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Genetic testing for HP is available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

RATIONALE

Summary of Evidence

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

For individuals who have chronic pancreatitis (CP) or acute recurrent pancreatitis (ARP) who receive testing for genes associated with hereditary pancreatitis (HP), the evidence includes cohort studies on variant detection rates and meta-analyses. Relevant outcomes are symptoms, change in disease status, morbid events, and hospitalizations. There are studies on the detection rate of HP-associated genes in various populations. Few studies have enrolled patients with known HP; those doing so have reported detection rates for disease-associated variants between 52% and 62%. For other studies that tested patients with CP or ARP, disease-associated variant detection rates varied widely across studies. There is a lack of direct evidence that testing for HP improves health outcomes and insufficient indirect evidence that, in patients with CP or ARP, management would change after genetic testing in a manner likely to improve health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are asymptomatic with family members with HP who receive testing for a known familial variant associated with HP, the evidence includes a very limited number of studies. Relevant outcomes are symptoms, change in disease status, morbid events, and hospitalizations. No direct evidence was identified comparing outcomes in patients tested or not tested for a familial variant. It is possible that at-risk relatives who are identified as having a familial variant may alter lifestyle factors (e.g., diet, smoking, alcohol use), and this might delay or prevent CP onset. However, studies evaluating behavioral changes and the impact on disease are lacking. The evidence is insufficient to determine the effects of the technology on health outcomes.

DEFINITIONS

NA

DISCLAIMER

Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.

CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

Procedure Codes								
81220	81221	81222	81223	81401	81404	81405	81479	

ICD-10-CM Diagnosis Codes	Description
K85.00	Idiopathic acute pancreatitis without necrosis or infection
K85.01	Idiopathic acute pancreatitis with uninfected necrosis
K85.02	Idiopathic acute pancreatitis with infected necrosis
K85.10	Biliary acute pancreatitis without necrosis or infection
K85.11	Biliary acute pancreatitis with uninfected necrosis
K85.12	Biliary acute pancreatitis with infected necrosis
K85.20	Alcohol induced acute pancreatitis without necrosis or infection
K85.21	Alcohol induced acute pancreatitis with uninfected necrosis
K85.22	Alcohol induced acute pancreatitis with infected necrosis
K85.30	Drug induced acute pancreatitis without necrosis or infection
K85.31	Drug induced acute pancreatitis with uninfected necrosis
K85.32	Drug induced acute pancreatitis with infected necrosis
K85.80	Other acute pancreatitis without necrosis or infection
K85.81	Other acute pancreatitis with uninfected necrosis
K85.82	Other acute pancreatitis with infected necrosis
K85.90	Acute pancreatitis without necrosis or infection, unspecified
K85.91	Acute pancreatitis with uninfected necrosis, unspecified
K85.92	Acute pancreatitis with infected necrosis, unspecified
K86.1	Other chronic pancreatitis

REFERENCES

1. Whitcomb DC. Value of genetic testing in the management of pancreatitis. *Gut*. Nov 2004; 53(11): 1710-7. PMID 15479696
2. Solomon S, Whitcomb DC, LaRusch J. PRSS1-Related Hereditary Pancreatitis. In: Adam MP, Ardinger HH, Pagon RAW, S.E., et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2012.
3. Fink EN, Kant JA, Whitcomb DC. Genetic counseling for nonsyndromic pancreatitis. *Gastroenterol Clin North Am*. Jun 2007; 36(2): 325-33, ix. PMID 17533082
4. Whitcomb DC. Framework for interpretation of genetic variations in pancreatitis patients. *Front Physiol*. 2012; 3: 440. PMID 23230421

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

5. Rosendahl J, Witt H, Szmola R, et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. *Nat Genet.* Jan 2008; 40(1): 78-82. PMID 18059268
6. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology.* Jun 2013; 144(6): 1252-61. PMID 23622135
7. Applebaum-Shapiro SE, Finch R, Pfützer RH, et al. Hereditary pancreatitis in North America: the Pittsburgh-Midwest Multi-Center Pancreatic Study Group Study. *Pancreatology.* 2001; 1(5): 439-43. PMID 12120221
8. Ceppa EP, Pitt HA, Hunter JL, et al. Hereditary pancreatitis: endoscopic and surgical management. *J Gastrointest Surg.* May 2013; 17(5): 847-56; discussion 856-7. PMID 23435738
9. Weiss FU, Hesselbarth N, Párnitzky A, et al. Common variants in the CLDN2-MORC4 and PRSS1-PRSS2 loci confer susceptibility to acute pancreatitis. *Pancreatology.* Jul 2018; 18(5): 477-481. PMID 29884332
10. Zou WB, Tang XY, Zhou DZ, et al. SPINK1, PRSS1, CTRC, and CFTR Genotypes Influence Disease Onset and Clinical Outcomes in Chronic Pancreatitis. *Clin Transl Gastroenterol.* Nov 12 2018; 9(11): 204. PMID 30420730
11. Vue PM, McFann K, Narkewicz MR. Genetic Mutations in Pediatric Pancreatitis. *Pancreas.* Aug 2016; 45(7): 992-6. PMID 26692446
12. Saito N, Suzuki M, Sakurai Y, et al. Genetic Analysis of Japanese Children With Acute Recurrent and Chronic Pancreatitis. *J Pediatr Gastroenterol Nutr.* Oct 2016; 63(4): 431-6. PMID 27409067
13. Koziel D, Gluszek S, Kowalik A, et al. Genetic mutations in SPINK1, CFTR, CTRC genes in acute pancreatitis. *BMC Gastroenterol.* Jun 23 2015; 15: 70. PMID 26100556
14. Schwarzenberg SJ, Bellin M, Husain SZ, et al. Pediatric chronic pancreatitis is associated with genetic risk factors and substantial disease burden. *J Pediatr.* Apr 2015; 166(4): 890-896.e1. PMID 25556020
15. Poddar U, Yachha SK, Mathias A, et al. Genetic predisposition and its impact on natural history of idiopathic acute and acute recurrent pancreatitis in children. *Dig Liver Dis.* Aug 2015; 47(8): 709-14. PMID 25981744
16. Masson E, Chen JM, Audrézet MP, et al. A conservative assessment of the major genetic causes of idiopathic chronic pancreatitis: data from a comprehensive analysis of PRSS1, SPINK1, CTRC and CFTR genes in 253 young French patients. *PLoS One.* 2013; 8(8): e73522. PMID 23951356
17. Wang W, Sun XT, Weng XL, et al. Comprehensive screening for PRSS1, SPINK1, CFTR, CTRC and CLDN2 gene mutations in Chinese paediatric patients with idiopathic chronic pancreatitis: a cohort study. *BMJ Open.* Sep 03 2013; 3(9): e003150. PMID 24002981
18. Sultan M, Werlin S, Venkatasubramani N. Genetic prevalence and characteristics in children with recurrent pancreatitis. *J Pediatr Gastroenterol Nutr.* May 2012; 54(5): 645-50. PMID 22094894
19. Gasiorowska A, Talar-Wojnarowska R, Czupryniak L, et al. The prevalence of cationic trypsinogen (PRSS1) and serine protease inhibitor, Kazal type 1 (SPINK1) gene mutations in Polish patients with alcoholic and idiopathic chronic pancreatitis. *Dig Dis Sci.* Mar 2011; 56(3): 894-901. PMID 20676769

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

20. Joergensen MT, Brusgaard K, Crüger DG, et al. Genetic, epidemiological, and clinical aspects of hereditary pancreatitis: a population-based cohort study in Denmark. *Am J Gastroenterol.* Aug 2010; 105(8): 1876-83. PMID 20502448
21. Rebours V, Boutron-Ruault MC, Schnee M, et al. The natural history of hereditary pancreatitis: a national series. *Gut.* Jan 2009; 58(1): 97-103. PMID 18755888
22. Keiles S, Kammesheidt A. Identification of CFTR, PRSS1, and SPINK1 mutations in 381 patients with pancreatitis. *Pancreas.* Oct 2006; 33(3): 221-7. PMID 17003641
23. Truninger K, Köck J, Wirth HP, et al. Trypsinogen gene mutations in patients with chronic or recurrent acute pancreatitis. *Pancreas.* Jan 2001; 22(1): 18-23. PMID 11138965
24. Culetto A, Bournet B, Haennig A, et al. Prospective evaluation of the aetiological profile of acute pancreatitis in young adult patients. *Dig Liver Dis.* Jul 2015; 47(7): 584-9. PMID 25861839
25. Bellin MD, Freeman ML, Gelrud A, et al. Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. *Pancreatol.* 2014; 14(1): 27-35. PMID 24555976
26. Chinnakotla S, Radosevich DM, Dunn TB, et al. Long-term outcomes of total pancreatectomy and islet auto transplantation for hereditary/genetic pancreatitis. *J Am Coll Surg.* Apr 2014; 218(4): 530-43. PMID 24655839
27. Teich N, Mössner J. Hereditary chronic pancreatitis. *Best Pract Res Clin Gastroenterol.* 2008; 22(1): 115-30. PMID 18206817
28. Müllhaupt B, Truninger K, Ammann R. Impact of etiology on the painful early stage of chronic pancreatitis: a long-term prospective study. *Z Gastroenterol.* Dec 2005; 43(12): 1293-301. PMID 16315124
29. Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. *Clin Gastroenterol Hepatol.* Mar 2004; 2(3): 252-61. PMID 15017610
30. Paolini O, Hastier P, Buckley M, et al. The natural history of hereditary chronic pancreatitis: a study of 12 cases compared to chronic alcoholic pancreatitis. *Pancreas.* Oct 1998; 17(3): 266-71. PMID 9788540
31. Hu C, Wen L, Deng L, et al. The Differential Role of Human Cationic Trypsinogen (PRSS1) p.R122H Mutation in Hereditary and Nonhereditary Chronic Pancreatitis: A Systematic Review and Meta-Analysis. *Gastroenterol Res Pract.* 2017; 2017: 9505460. PMID 29118810
32. Takáts A, Berke G, Gede N, et al. Risk of chronic pancreatitis in carriers of loss-of-function CTRC variants: A meta-analysis. *PLoS One.* 2022; 17(5): e0268859. PMID 35594281
33. Tenner S, Baillie J, DeWitt J, et al. American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol.* Sep 2013; 108(9): 1400-15; 1416. PMID 23896955
34. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* Feb 2015; 110(2): 223-62; quiz 263. PMID 25645574
35. Gardner TB, Adler DG, Forsmark CE, et al. ACG Clinical Guideline: Chronic Pancreatitis. *Am J Gastroenterol.* Mar 2020; 115(3): 322-339. PMID 32022720

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

36. Conwell DL, Lee LS, Yadav D, et al. American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. *Pancreas*. Nov 2014; 43(8): 1143-62. PMID 25333398
37. Grody WW, Cutting GR, Klinger KW, et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. *Genet Med*. 2001; 3(2): 149-54. PMID 11280952
38. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. *Genet Med*. 2004; 6(5): 387-91. PMID 15371902
39. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. *Genet Med*. Jun 2013; 15(6): 482-3. PMID 23619275
40. Deignan JL, Astbury C, Cutting GR, et al. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. Aug 2020; 22(8): 1288-1295. PMID 32404922
41. Whitcomb DC, Shimosegawa T, Chari ST, et al. International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with The International Association of Pancreatology, American Pancreatic Association, Japan Pancreas Society, PancreasFest Working Group and European Pancreatic Club. *Pancreatology*. Jul 2018; 18(5): 516-527. PMID 29793839
42. Hegyi P, Párnitzky A, Lerch MM, et al. International Consensus Guidelines for Risk Factors in Chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. *Pancreatology*. Jun 2020; 20(4): 579-585. PMID 32376198
43. Gariepy CE, Heyman MB, Lowe ME, et al. Causal Evaluation of Acute Recurrent and Chronic Pancreatitis in Children: Consensus From the INSPPIRE Group. *J Pediatr Gastroenterol Nutr*. Jan 2017; 64(1): 95-103. PMID 27782962
44. Stoffel EM, McKernin SE, Brand R, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. *J Clin Oncol*. Jan 10 2019; 37(2): 153-164. PMID 30457921
45. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 2.2025. November 7, 2024.

POLICY HISTORY

MP 2.318	02/14/2019 Consensus Review. No changes to the policy statements. Background and references updated. Rationale revised. Appendix removed.
	04/07/2020 Consensus Review. No changes to policy statements. Coding reviewed, added the following diagnosis codes: K85.90, K85.91, and K85.92.

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR HEREDITARY PANCREATITIS
POLICY NUMBER	MP 2.318

04/14/2021 Consensus Review. No change to policy statement. Two new codes added 81220 and 81221. Tables updated to correct format
06/14/2022 Consensus Review. No changes to policy statement. References updated and coding reviewed.
01/20/2023 Minor Review. Policy statement changed to include criteria for genetic testing of all ages. Rationale updated. References updated and added. NCCN statement added. Coding reviewed.
01/22/2024 Consensus Review. No changes to policy statement. References updated and coding reviewed.
11/19/2024 Administrative Update. Removed NCCN statement.
02/13/2025 Minor Review. Policy statement changed to 18 years and younger and states acute recurrent (>1 episode). References updated. Coding reviewed.
06/11/2025 Administrative Update. Removing the Benefit Variations Section and updating the Disclaimer.
01/06/2026 Consensus Review. No changes to policy statement. Updated product variations, background, rationale, and references. No coding changes.
03/05/2026 Retirement Review. Evicore delegation.

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.